Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Stocks soared Wednesday as investors digested strong earnings reports from several large financial services companies and ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...